SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cyclacel Pharmaceuticals, Inc. Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 American Society of Hematology Annual Meeting
Your Message